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Background: HIV drugs lopinavir and ritonavir have been recently 
reported to cause transient adrenal insufficiency in preterm newborns. 
We, therefore, considered HIV drugs as a cause of transient elevation 
of 17-hydroxyprogesterone (17OHP) in a neonatal screening test for 
congenital adrenal hyperplasia (CAH) in a preterm girl exposed to 
zidovudine, efavirenz, tenofovir, and emtricitabine.  
Objective: So far HIV drugs have not been tested for their effect on 
steroidogenesis and steroidogenic enzyme CYP21A2 specifically in an 
in vitro system.   
Methods: We tested the effect of efavirenz, tenofovir, emtricitabine, and 
zidovudine on steroidogenesis of human adrenal H295R cells. Cells 
were treated with drugs at different concentrations including 
concentrations in therapeutic use. The effect on CYP21A2 activity was 
assessed by testing the conversion of radiolabeled 17OHP to 11-
deoxycortisol. Cell viability was tested by an MTT assay. In addition, 
recombinant produced and purified human CYP21A2 protein was used 
to assess the direct drug effect on CYP21A2 activity.  
Results: We observed significantly decreased CYP21A2 activity in both 
in vitro testing systems after treatment with efavirenz at therapeutic 
concentrations. Moreover, efavirenz affected cell viability. By contrast, 
the other test drugs did not affect steroidogenesis. Follow-up of our 
patient revealed elevated 17OHP and androgens during the first weeks 
of life, but values normalized spontaneously. Genetic testing for 
CYP21A2 mutations was negative. Thus whether transient elevation of 
17OHP in this baby was due to a drug effect remains unsettled. 
Conclusion: The HIV drug efavirenz inhibits CYP21A2 activity in vitro 
through direct interaction with enzyme catalysis at therapeutic 
concentrations. This may have clinical implications for HIV treatment in 
children and adults. However, so far clinical data are scarce, and further 
studies are needed to draw clinical conclusions. 
 
1. Introduction 
Adrenal insufficiency (AI) may be a life-threatening 
condition due to inadequate production of 
glucocorticoids and mineralocorticoids. It is classified 
as primary AI (PAI), with the underlying cause in the 
adrenals and as secondary AI, with the underlying 
defect in the hypothalamic-pituitary control of the 
adrenals. In newborns, congenital adrenal hyperplasia 
(CAH) due to genetic mutations in the CYP21A2 gene 
is the leading cause of PAI and affects about 1 in 
10’000 - 15’000 newborns in Europe (1-3). CYP21A2 
is essential for both mineralocorticoid and 
glucocorticoid production because it mediates the 21-
hydroxylation of progesterone to deoxycorticosterone 
and 17-hydroxyprogesterone (17OHP) to 11-
deoxycortisol (2). The severe, classic, salt-wasting 
form of CYP21A2 deficiency is a potentially life-
threatening condition characterized by low or absent 
production of cortisol and aldosterone as well as 
overproduction of adrenal androgens and manifests 
early in life (1-4). The milder, non-classic form of CAH 
may manifests later in life predominantly with 
consequences of adrenal androgen excess. While girls 
with classic CAH often manifest with ambiguous 
genitalia at birth due to intrauterine overproduction of 
androgens (5), boys do not show physical signs 
suggestive of CAH (4,6). Therefore many countries 
have introduced a neonatal screening program for 
early diagnosis of CAH based on blood 17OHP levels 
reflecting CYP21A2 enzyme deficiency (3,6). 
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However, 17OHP blood screening by heel-stick may 
reveal both false positive and false negative results. 
Especially challenging is the interpretation of elevated 
results in preterm (7) or stressed newborns (8). Also, 
17OHP may be elevated in other rarer forms of CAH 
such as HSD3B2, CYP11B2 or P450 oxidoreductase 
deficiencies, which also require prompt corticosteroid 
replacement therapy (9,10). Furthermore, the activities 
of adrenal enzymes can be influenced by drugs and 
toxins, and thereby cause PAI in rare cases. Drugs 
such as ketoconazole, metyrapone, etomidate, 
mitotane, and abiraterone are known inhibitors of 
steroid enzymes including CYP11A1, CYP17A1, 
CYP21A2 and CYP11B1/2 (11,12).  
In recent clinical studies, it has been suggested that 
some HIV drugs may also affect steroidogenesis. 
Elevated serum 17OHP and dehydroepiandrosterone 
(DHEA) levels were found in neonates treated 
perinatally with HIV-1 protease inhibitors lopinavir and 
ritonavir (13,14). Three premature babies presented 
with clinical and biochemical signs of adrenal 
dysfunction after postnatal treatment with these drugs 
(13), while a full-term neonate was noted to have high 
serum 17OHP and potassium levels after pre- and 
postnatal treatment with lopinavir and ritonavir (14). In 
our clinic, we also followed a preterm baby of an HIV 
infected mother for repeatedly high levels of 17OHP in 
neonatal screening. Drugs efavirenz, emtricitabine, 
and tenofovir (Atripla®) were prescribed to the mother 
during pregnancy to reduce the mother to child 
transmission of HIV, and the neonate was treated with 
zidovudine for prevention postnatally. According to 
current literature (these) HIV drugs have not been 
tested for a possible effect on steroidogenesis. 
The World Health Organization (WHO) reported in 
2017 that about 18 million women worldwide were 
infected with HIV. They also reported that HIV 
treatment during pregnancy was very effective and 
reduced the mother to child transmission of an HIV 
infection from 45% to 2% (15). However, this means 
that a significant number of neonates are exposed to 
HIV drugs very early in life, and possible adverse 
effects of drugs might be of significance.   
Therefore, motivated by the clinical observations and 
stimulated by the fact that none of the HIV drugs in 
routine use have been tested for an effect on adrenal 
steroidogenesis, we tested some of these drugs for 
their effect on steroidogenesis, specifically on 
CYP21A2 activity in vitro. 
 
2. Materials and Methods 
 
Case Report  
A 46, XX baby girl was born at 26 weeks gestation after 
premature rupture of membranes to an HIV infected 
mother. Birth weight was 760g (P 40), length 35cm (P 
60). Because of premature contractions, the mother 
received 2 doses of betamethasone at 23 5/7 weeks 
gestation for induction of lung maturation. In addition, 
the mother was treated with HIV drugs tenofovir, 
efavirenz and emtricitabine (Atripla®) throughout 
pregnancy. The newborn was then treated with 
zidovudine for (post-)exposure prophylaxis during the 
first four weeks of life (Figure 1). The girl showed a 
normal physical exam at birth including normal female 
external genitalia without signs of virilization but 
received a single dose of hydrocortisone (0.1mg/kg) for 
low blood pressure. Initial laboratory workup in serum 
revealed normoglycemia, normal electrolytes and a 
normal 17OHP (80 nmol/l; reference value for GA and 
postnatal age <192nmol/l). But while glucose and 
electrolytes remained normal, 17OHP increased to 
292nmol/l on day 15 (norm for GA and age <141nmol/l) 
and was 132nmol/l on day 19 (norm <104nmol/l; 
DELFIA Neonatal 17αOH-progesterone kit, 
PerkinElmer, Switzerland), and prompted further 
workup for possible CAH. ACTH (8.3ng/l; reference 
range 7.2-63.3) and cortisol (396 nmol/l; reference 
range 171-536nmol/l) were both normal at three weeks 
of age. Urine steroid profiling (GC-MS) at 3 and 6 
weeks of age revealed elevated progesterone and 
androgen metabolites. Finally, serum 17OHP 
normalized after four weeks (Figure 1) and the clinical 
course was completely unremarkable. The baby was 
discharged home at the postconceptional age of 36 1/7 
weeks. She is currently 3 years old and healthy. 
 
Urinary steroid profiling 
Urinary steroid profiling was performed by an 
established, validated in-house method of gas 
chromatography-mass spectrometry (GC-MS) (16-19). 
Measurements of spot urines (collected from cotton 
balls inserted in diapers) were normalized to creatinine 
(QuantiChrom Creatinine Assay; DICT-500, BioAssay 
Systems, Hayward, CA, USA). Accordingly, results are 
expressed in µg/mmol creatinine (Supplemental Table 
1) as previously described for healthy neonates during 
the first year of life (16-18). 
 
Genetic analysis of the CYP21A2 gene 
Three fragments of the CYP21A2 gene were amplified 
by PCR from genomic DNA using the CAH 
StripAssay® (ViennaLab Diagnostics, Vienna, 
Austria). In addition, all coding sequences of the 
CYP21A2 gene were sequenced with the Sanger 
method using internal sequencing primers. For 
analysis, the CYP21A2 reference sequence 
NM_000500.6 was used. 
 
In vitro cell assays 
Material: Antiretroviral HIV drugs zidovudine (3'-azido-
3'deoxythymidine) and efavirenz were purchased from 
Sigma-Aldrich (Buchs, Switzerland), tenofovir and 
emtricitabine from Toronto research chemicals 
(Brisbane, Canada). Radio-labeled [3H]-17-
hydroxyprogesterone (17OHP; 50 Ci/mmol) was from 
American Radiolabel Chemicals Inc. (St. Louis, MO, 
USA). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was obtained from 
Sigma-Aldrich (Buchs, Switzerland). The human 
adrenal carcinoma cell line NCI-H295R originates from 
American Type Culture Collection (ATCC).  
NCI-H295R cells were cultured under standard 
conditions (12,20). Test drugs were dissolved in 
dimethyl sulfoxide (DMSO); final concentrations used 
for treatment were in and above reported mean 
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effective serum concentrations in use for HIV therapy. 
Cells were grown in twelve well plates. Drugs were 
added to normal growth medium for 3 and 24 h. Control 
cells were treated with 0.1% (v/v) DMSO. Radio-
labeled [3H]-17-hydroxyprogesterone (50,000 
cpm/well) was added to the culture medium for the last 
90 min of incubation. Steroids were then extracted from 
cell supernatants and separated by thin layer 
chromatography (TLC) as described (21). Steroids 
were visualized on a Fuji PhosphoImager FLA-7000 
(Fujifilm, Dielsdorf, Germany) and densitometrically 
quantified using Multi Gauge software (Fujifilm). The % 
conversion of 17OHP to 11-deoxycortisol (11DOC) 
was taken as a measure of CYP21A2 activity.  
 
The MTT cell proliferation assay was used to 
determine cell viability and proliferation of NCI-H295R 
cells treated with HIV drugs. In brief, cells were cultured 
on 96-well plates at a density of 15’000 cells/well in 200 
µl medium. After 48 hours cells were treated with the 
HIV drugs for 3 and 24 hours. Then cell proliferation 
was assessed by adding 20 µl of MTT to the culture 
medium for 3 hours before reading the absorbance at 
540 nm on a Spectramax M2e microplate reader 
(Molecular Devices, CA, USA). In this assay, the 
absorbance at 540 nm correlates directly to the number 
of viable cells. 
 
In vitro studies with recombinant CYP21A2 protein 
Human CYP21A2 protein was expressed in E. coli 
strain C43(DE3) (Lucigen, Middleton, MI, USA) and 
purified via metal chelate (IMAC) and ion exchange 
chromatography as described (22). Carbon monoxide 
difference spectroscopy was carried out for a 
quantitative enzyme characterization following the 
typical absorption maximum at 450 nm with an 
extinction coefficient of 91 mM−1cm−1. Human NADPH-
cytochrome P450 reductase (POR) was expressed in 
E. coli C43 (DE3) and purified by IMAC as described 
(23). 
Inhibition studies were performed in reconstituted in 
vitro assays in 50 mM HEPES buffer (pH 7.4) 
containing 20% glycerol and 100 µM 1,2-dilauroyl-sn-
glycerol-3-phosphocholine. Before use, the buffer was 
sonicated in a water bath for 5 minutes for the 
reconstitution of 1,2-dilauroyl-sn-glycero-3-
phosphocholine vesicles. The final concentration of 
human CYP21A2 was 0.1 µM, and equal amounts of 
human POR were added. Additionally, the reaction 
contained an NADPH regeneration system consisting 
of 5 mM glucose-6-phosphate, 1 mM MgCl2 and 
glucose-6-phosphate dehydrogenase. The steroid 
substrate 17OHP was added at a concentration of 5 
µM and the drugs were tested at 5 or 50 µM 
concentration. The substrate concentrations were kept 
below saturation, but in excess over the Km for 
CYP21A2. The final DMSO concentration was kept 
below 2%. The reaction was started with 5 mM NADPH 
and incubated in a shaking water bath for 4 - 7 min at 
37°C. The reaction was quenched with chloroform. 
Steroids were extracted twice with chloroform, dried 
and stored at -20°C for HPLC analysis, specifically the 
measurement of 17OHP conversion to 11DOC. 
Steroid analysis was finally carried out by RP-HPLC 
using a Jasco reversed phase HPLC system of the 
LC900 series (Jasco Inc, Easton, MD, USA) and a 4.6 
mm × 125 mm NucleoDur C18 Isis Reversed Phase 
column (Macherey-Nagel, Düren, Germany). Samples 
were measured within 30 min at 240 nm and a flow rate 
of 0.8 mL/min with the gradient: 80% solvent A (10% 
acetonitrile in water) for 13 min, 60% solvent A for 7 
min, 80% solvent B (100% acetonitrile) for 2 min and 
80% solvent A for 8 min. 
 
 
Figure 1: Transiently elevated serum 17-
hydroxyprogesterone (17OHP) levels in a newborn under the 
influence of Atripla® (efavirenz, tenofovir, emtricitabine) 
prenatally and Retrovir® (zidovudine) during 4 weeks 
postnatally. Note that the newborn received one dose of 
hydrocortisone in the first 24 hours after birth. Peak 17OHP 
levels were seen at d15 and normalized by d28 according to 
normative values of the Swiss 17OHP neonatal screening 
test. 
 
In silico protein structure analysis 
A 3D crystal structure of human CYP21A2 was 
obtained from the PDB database (www.rcsb.org) for 
docking analysis of efavirenz binding (24). However, 
the structure (PDB # 4Y8W) has multiple residues 
missing that creates gaps in the peptide backbone 
making it unstable during molecular dynamics analysis. 
A model building using sequence conservation 
information and secondary structure analysis was 
needed to fill the gaps and create a complete structure 
suitable for docking and molecular dynamics 
calculations. To get the secondary structure 
information of missing residues we performed 
sequence alignments with multiple CYP21A2 protein 
sequences from different organisms (Supplementary 
Figure 1) and made in-silico calculations with the 
programs YASARA (25) and WHATIF (26). Missing 
hydrogen atoms were added with YASARA (25) which 
was also used for all subsequent computations unless 
stated otherwise. Afterward, the system was subjected 
to 500 ps explicit solvent MD simulations at 310 K, 
preceded by 500 steps of steepest descent and 
simulated annealing minimization with the AMBER15 
force field and the TIP3P water model (27,28). All 
subsequent MD simulations retained these settings. 
The resulting minimum energy structure was used with 
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AutoDock Vina (29) for docking experiments with 
efavirenz. Orthorhombic docking was grid established 
around the central heme. The final poses were 
selected based on their docking scores and 
resemblance to the co-crystallized progesterone in the 
template structure (PDB: 4Y8W). Structure models 
were depicted with Pymol (www.pymol.org) and 
rendered as ray-traced images with POVRAY 
(www.povray.org). Ligand interactions were 
analyzed.and depicted with LIGPLOT+ 
(http://www.ebi.ac.uk/thornton-srv/software/LigPlus/). 
Statistical analysis  
Statistical analysis was performed with Microsoft Excel 
and software Prism 6 (Graph Pad Software, Inc. San 
Diego, CA, USA). Student’s t-test was used to evaluate 
the significance of differences between values. 
Quantitative data represent the mean of two or three 
independent experiments; error bars indicate the 
mean ± SEM. Significance was set at *p < 0.05 and 
**p < 0.01, ***p < 0.001.  
 
 
 
Figure 2 –Efavirenz inhibits CYP21A2 activity at concentrations in therapeutic use, while no effect was seen for the other 
tested HIV drug compounds. Human adrenal NCI-H295R were treated with efavirenz, emtricitabine, tenofovir, and zidovudine 
in various concentrations for 3 and 24 hours to test for their effect on steroidogenesis. Steroids were extracted from cell 
supernatants and separated by thin layer chromatography (TLC). Relative CYP21A2 activity was calculated by assessing the 
conversion of 17-hydroxyprogesterone (17OHP) to 11-deoxycortisol  (11DOC). Data are the mean ± SEM of two to four 
independent experiments. *p < 0.05 and **p < 0.01, ***p < 0.001 
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3. Results  
Biochemical data of neonates exposed to HIV drugs 
lopinavir and ritonavir suggested an inhibitory effect on 
adrenal steroidogenesis (13,14). Similarly, we 
observed elevated serum 17OHP levels and urinary 
steroid profile abnormalities consistent with diminished 
CYP21A2 and maybe diminished CYP17A1 activities 
in a preterm girl after exposure to tenofovir, efavirenz 
and emtricitabine in utero, and zidovudine postnatally  
(see Case Report; Figure 1). Genetic testing excluded 
mutations in the CYP21A2 gene.  
 
Efavirenz inhibits CYP21A2 activity  
The effect on steroidogenesis of antiviral HIV drugs 
zidovudine, emtricitabine, tenofovir, and efavirenz was 
tested in the adrenal H295R cell line. Efavirenz is a 
non-nucleoside reverse transcriptase inhibitor. Its 
reported mean effective serum concentration is 1.6-
9.1μM 
(https://www.medicines.org.uk/emc/product/8659/smp
c). The drug was tested at four concentrations (1μM, 
5μM, 10μM, 50μM) after 3h and 24h incubation. A 
significant decrease of CYP21A2 activity was observed 
after 3h incubation starting at 5μM (p < 0.05), with a 
clear additional dose effect at higher concentrations 
(10μM, 50μM; p < 0.01, p < 0.001) (Figure 2, left panel). 
By contrast, after 24h incubation CYP21A2 inhibition 
was only observed at the highest (50μM) efavirenz 
concentration (p < 0.001) suggesting that longer 
incubation may allow the cells to compensate for the 
drug effect to some degree (Figure 2, right panel).  
 
Zidovudine and emtricitabine are nucleoside reverse 
transcriptase inhibitors. Reported mean effective 
serum concentration for zidovudine is 4.45μM - 8.5μM 
(https://www.medicines.org.uk/emc/product/6811/smp
c) and for emtricitabine it is 4.5μM - 10μM 
(https://www.medicines.org.uk/emc/product/18/smpc), 
respectively. H295R cells were treated with zidovudine 
and emtricitabine in two concentrations (10µM and 
50µM) for 3h and 24h. Both drugs showed no effect on 
CYP21A2 activity at either timing (Figure 2). Tenofovir 
is also a nucleoside reverse transcriptase inhibitor, but 
by contrast to zidovudine and emtricitabine its mean 
effective serum concentration is markedly lower (0.74 
- 1.13 µM) 
(https://www.medicines.org.uk/emc/product/771/smpc
). Therefore, tenofovir was tested at lower 
concentrations of 1 and 5µM for 3 and 24h. No effect 
on CYP21A2 activity was observed (Figure 2). 
 
As the HIV drugs efavirenz, tenofovir, and emtricitabine 
are often in use as triple medication Atripla®, we also 
tested the three compounds together in our H295R cell 
system. These experiments revealed the same 
inhibitory effect on CYP21A2 as observed with 
efavirenz alone (Figure 2, bottom).  
 
Furthermore, to assess whether the tested drugs may 
affect H295R cell viability, we performed an MTT cell 
proliferation assay. Efavirenz starting at 5µM reduced 
cell proliferation significantly compared to control cells 
Efavirenz at 10 and 50µM seemed extremely cytotoxic. 
The same effect was also observed in H295R cells 
treated with the combination drug Atripla®, while no 
effect was seen with single treatments of zidovudine, 
emtricitabine, and tenofovir.  
 
Efavirenz is a direct inhibitor of CYP21A2 activity 
We also tested the direct effect of the four HIV drugs 
on enzyme catalysis using human recombinant 
CYP21A2 protein and 17OHP as a substrate. Similar 
to the cell culture experiments, we found that efavirenz 
inhibited CYP21A2 activity to a significant degree, 
decreasing the product formation to 30 % at a 
concentration of 50 µM efavirenz (Figure 3). By 
contrast, no effect on enzyme activity was found for the 
other three test drugs (Figure 3). 
 
 
Figure 3 – Effect of HIV-drugs on CYP21A2 activity using 
human recombinant CYP21A2 protein produced in bacteria. 
Protein was produced as published. CYP21A2 activity was 
tested with 5 µM 17OHP as substrate and HIV-drugs at 
following concentrations: emtricitabine 50 µM, efavirenz 50 
µM, zidovudine 50 µM, and tenofovir 5 µM. Steroids were 
extracted and analyzed by RP-HPLC (see Methods). 
 
Computational docking of efavirenz into the human 
CYP21A2 crystal structure  
Efavirenz was docked into the crystal structure of 
human CYP21A2 using Autodock VINA (Figure 4A). 
Superimposition of CYP21A2 structures with either 
progesterone or efavirenz docked into the active site 
revealed similarities in binding poses (Figure 4B and 
4C). We observed a distance of 2.8 Å between 
efavirenz and heme iron at the active site of CYP21A2 
(Figure 4A). Efavirenz is a smaller molecule than 
progesterone and may achieve several potential 
binding poses inside the CYP21A2. However, the 
occupation of the CYP21A2 catalytic site by efavirenz 
would inhibit the binding and metabolism of CYP21A2 
steroid substrates. A comparison of the CYP21A2 and 
CYP17A1 crystal structures in complex with steroid 
substrates and docked efavirenz into the crystal 
structure of CYP21A2 revealed similarities in 
interacting residues and the distance of the efavirenz 
nitrogen to the central heme iron of CYP21A2 was in 
similar range (Figure 4A). Binding of efavirenz with 
CYP21A2 shares many similarities with natural 
substrates of CYP21A2 with identical active site 
residues such as Ser109, Gly292, and Leu364 
involved in binding for both chemicals (Figure 4B and 
4C).
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Figure 4 –Structure analysis of HIV-drug efavirenz interaction with the CYP21A2 enzyme. A.  Efavirenz docked into the protein 
structure of CYP21A2. B. Progesterone versus C. Efavirenz binding poses revealed by the CYP21A2 structure and docking 
studies. 
 
4. Discussion 
Laboratory investigations of neonates exposed to HIV 
drugs suggest that these compounds may alter adrenal 
steroidogenesis (13,14). However, so far these drugs 
had not been tested for their possible effect on adrenal 
steroidogenesis. In this study, we show that the 
antiretroviral drug efavirenz inhibits steroidogenic 
enzyme CYP21A2 at therapeutic concentrations in 
human adrenal NCI-H295R cells and in direct kinetic 
protein interaction assays. Our bioinformatic studies 
suggest that efavirenz is a direct competitor to 
substrates of the enzyme. By contrast, no inhibitory 
effect on CYP21A2 activity was found for zidovudine, 
emtricitabine, tenofovir. 
 
Medications in use for HIV treatment fall in different 
categories concerning drug safety 
(https://aidsinfo.nih.gov/guidelines). Tested drugs 
suspected to inhibit steroidogenesis are listed in the 
category characterized by limited experience in 
pregnancy and with incomplete data on teratogenicity, 
toxicity and drug interactions. In literature, efavirenz 
has been linked to congenital anomalies in monkeys 
and humans in some studies 
(https://aidsinfo.nih.gov/guidelines, (30,31)), but these 
adverse effects were not confirmed in others (32,33). 
Currently no restrictions apply to the use of efavirenz 
during pregnancy, neither in British nor US HIV 
treatment guidelines 
(https://www.bhiva.org/pregnancy-guidelines and 
https://aidsinfo.nih.gov/guidelines). Fetal exposure to 
tenofovir was shown to lower bone mineral content in 
infants compared to controls (34). By contrast, no 
congenital anomalies or adverse effects have been 
reported with the HIV drug emtricitabine (33,35,36).  
Concerning interactions of HIV drugs with cytochrome 
P450 enzymes, nothing was known for steroidogenic 
P450s so far. But ritonavir has been reported to inhibit 
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drug metabolizing CYP2D6 and CYP3A4 (37,38), while 
an enzyme induction of ritonavir/lopinavir on CYP1A2 
and CYP2C9 and CYP2C19 activities has been 
observed (39). These drugs have not been tested for 
their effect on CYP21A2 in this studies, but are 
currently being tested in cell experiments with 
preliminary results showing an inhibitory effect of 
lopinavir but not ritonavir on CYP21A2 and less on 
CYP17A1.  
 
Overall these results suggest that HIV drugs 
should be carefully tested for their possible effect on 
P450s including steroidogenic P450 enzymes as this 
may have clinical implications. Mild inhibition of adrenal 
steroid biosynthesis may not have consequences in 
healthy individuals, but can result in inability to sustain 
stressful situations with severe disease where within 
minutes there is a high demand for stress hormones. 
In addition, long term lowgrade inhibition of CYP21A2 
or other steroid enzyme activities may lead to an 
imbalance between adrenal corticosteroids and 
androgens with all its consequences. This is best 
exemplified by late-onset CAH due to mild CYP21A2 
deficiency. Such effect may also result from 
medications interfering with steroid enzyme activities 
as shown for antiepileptic drugs, which can cause an 
increase in androgen production and a polycystic ovary 
syndrome phenotype (40,41).  
 
The premature baby described in our case 
report showed positive newborn screening for transient 
elevation of plasma 17OHP and increased urinary 
excretion of androgens, estrogens and progesterones 
after treatment with HIV drugs during fetal life 
(tenofovir, efavirenz, emtricitabine) and postnatally 
(zidovudine). While elevated plasma 17OHP with 
neonatal screening motivated us to investigate the 
effect of the HIV drugs in question on CYP21A2 
activity, elevated urinary excretion of progesterones 
may not be explained by CYP21A2 inhibition but rather 
by CYP17A1 deficiency. On the other hand, CYP17A1 
deficiency decreases androgen production. Thus the 
abnormal biochemical findings in our case with 
spontaneous resolution may or may not have been due 
to an adverse drug effect (of efavirenz). However, our 
in vitro and in silico studies show that such an effect is 
clearly seen for efavirenz. Its impact should be further 
explored in larger clinical studies. It is therefore 
important to bring the possible inhibitory effect of HIV 
drugs on adrenal steroidogenesis to the attention of the 
HIV community, as it may have clinical implications 
beyond the neonatal age.  
 
In conclusion, HIV drug efavirenz inhibits 
CYP21A2 activity in human adrenal NCI-H295R cells 
at therapeutic concentrations apparently by a 
competitive mechanism. This effect has been 
suspected by laboratory abnormalities found in few 
newborns treated with HIV drugs. Whether this effect 
is of clinical relevance to the adrenal function in health 
and disease remains to be seen in larger clinical 
studies including children and adults under treatment 
with HIV drugs. So far we suggest to list some HIV 
drugs (such as efavirenz) as medications that may 
cause a positive neonatal screening test for elevated 
17OHP.  
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